ml-3000 has been researched along with lysophosphatidylcholines in 1 studies
| Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) | Studies (lysophosphatidylcholines) | Trials (lysophosphatidylcholines) | Recent Studies (post-2010) (lysophosphatidylcholines) |
|---|---|---|---|---|---|
| 130 | 9 | 56 | 5,058 | 39 | 976 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M; Martel-Pelletier, J; Pelletier, JP; Rahman, P; Randell, EW; Zhai, G | 1 |
1 trial(s) available for ml-3000 and lysophosphatidylcholines
| Article | Year |
|---|---|
Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cyclooxygenase Inhibitors; Female; Humans; Lysophosphatidylcholines; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Phosphatidylcholines; Pyrroles; Treatment Outcome | 2019 |